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Summary
 
To generate peptides for presentation by major histocompatibility complex (MHC) class I mol-
ecules to T lymphocytes, the immune system of vertebrates has recruited the proteasomes,
phylogenetically ancient multicatalytic high molecular weight endoproteases. We have previ-
ously shown that many of the proteolytic fragments generated by vertebrate proteasomes have
structural features in common with peptides eluted from MHC class I molecules, suggesting
that many MHC class I ligands are direct products of proteasomal proteolysis. Here, we report
that the processing of polypeptides by proteasomes is conserved in evolution, not only among
vertebrate species, but including invertebrate eukaryotes such as insects and yeast. Unexpect-
edly, we found that several high copy ligands of MHC class I molecules, in particular, self-
ligands, are major products in digests of source polypeptides by invertebrate proteasomes. More-
over, many major dual cleavage peptides produced by invertebrate proteasomes have the length
and the NH
 
2
 
 and COOH termini preferred by MHC class I. Thus, the ability of proteasomes
to generate potentially immunocompetent peptides evolved well before the vertebrate immune
system. We demonstrate with polypeptide substrates that interferon 
 
g
 
 induction in vivo or ad-
dition of recombinant proteasome activator 28
 
a
 
 in vitro alters proteasomal proteolysis in such a
way that the generation of peptides with the structural features of MHC class I ligands is opti-
mized. However, these changes are quantitative and do not confer qualitatively novel charac-
teristics to proteasomal proteolysis. The data suggest that proteasomes may have influenced the
evolution of MHC class I molecules.
 
T
 
lymphocytes recognize peptide fragments of protein
antigens presented on the cell surface by the class I
and class II molecules of the MHC.The peptide fragments
are generated proteolytically inside the cell. MHC class II
molecules are loaded in a secretory compartment with pep-
tides generated in endosomes. MHC class I molecules are
loaded with peptides mainly generated in the cytoplasm
and transported into the ER/
 
cis
 
-Golgi by the peptide trans-
porter associated with antigen processing (TAP
 
1
 
; 1, 2). The
vast majority of peptides presented by MHC molecules are
derived from self-proteins. The peptide-binding grooves of
class II molecules are open at both ends and bind peptides
of heterogenous length (usually 12–25 amino acids [aa]);
the peptide-binding grooves of class I molecules are closed
at both ends and usually bind peptides of closely defined
length (8–10, mostly 9 aa). In the latter case, the peptide is
usually fixed by two allele-specific anchor residues that are
complementary to allele-specific pockets in the MHC class I
peptide-binding groove (3, 4). In addition, H bonds are
formed between relatively invariant polar aa at the ends of
the binding groove and the NH
 
2
 
 and COOH termini of
the peptide (5). Typically, one of the allele-specific pock-
ets, the COOH-terminal F pocket, accommodates an ali-
phatic, aromatic, or positively charged aa at the COOH ter-
minus of an octa/nonamer peptide. The second anchor may
 
1
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reside at the second, the third, or the fifth position from the
NH
 
2
 
 terminus of the peptide, and is more variable (3).
For the proteolytic generation of MHC class I epitopes,
the immune system of vertebrates appears to have recruited
the proteasomes. These ubiquitous multi-subunit endopro-
teases are phylogenetically ancient, as they occur in archea
and bacteria, as well in eukarya. In eukaryotic cells, protea-
somes appear to be the major proteolytic system of the nu-
cleus and the cytosol. Three main forms are observed. The
20S proteasome, by itself capable of degrading misfolded or
damaged polypeptides, represents the proteolytic core of the
larger and more complex 26S proteasomes and the 20S–
proteasome activator (PA)28 complexes (6). It has a barrel-
shaped hollow structure with four layers of rings, each
composed of seven subunits. The outer rings consist of pro-
teolytically inactive 
 
a
 
-type subunits, the inner rings of 
 
b
 
-type
subunits. Archaebacterial proteasomes possess one type of
proteolytically active 
 
b
 
 subunit, i.e., all seven members in a
 
b
 
 ring have a NH
 
2
 
-terminal threonine acting as the nu-
cleophile in peptide-bond hydrolysis. In eukaryotes, three
out of seven different 
 
b
 
-type subunits contain such a site.
Proteolysis takes places inside the central cavity, between
the two 
 
b
 
 rings (7, 8). In vertebrates, the three proteolytically
active 
 
b
 
-type subunits (X, Y, and Z) have IFN-
 
g
 
–inducible
homologues (LMP7, LMP2, and MECL1) replacing their
constitutive counterparts when induced. The PA28 protea-
some activator, giving rise to the 20S–PA28 complexes, is
IFN-
 
g
 
–inducible as well. LMP2 and LMP7, but not
MECL1 and PA28, are encoded by genes in the MHC (9).
The assembly of the class I heavy chain with 
 
b
 
2
 
 micro-
globulin (
 
b
 
2
 
m) can be substantially inhibited by peptide al-
dehydes, potent but not absolutely specific proteasome in-
hibitors (10). This seminal information, together with the
discovery of the MHC-encoded proteasome subunits (11),
have stimulated a host of investigations into the role of ver-
tebrate 20S proteasomes in the processing of antigens pre-
sented by MHC class I (for review see references 6 and 9).
Although most of these studies converged in suggesting a
major role for proteasomes in the generation of MHC class
I epitopes, it is also clear that the evidence in support of this
notion remains, to some extent, circumstantial. We have
recently reported that the length distribution of dual cleav-
age proteolytic fragments produced by mouse 20S pro-
teasomes centers around 8–11 mer. The frequencies of in-
dividual aa at the COOH termini of proteolytic fragments
generated by proteasomes correlated strikingly with that at
the corresponding positions of so far eluted MHC class I
ligands. For the NH
 
2
 
 termini too, a significant enrichment
of small and polar aa was observed for both proteasomal
degradation products and MHC class I ligands (12). Intrigu-
ingly, similar COOH and NH
 
2
 
 termini as well as a similar
length distribution were found for peptides preferentially
transported by TAP or by certain TAP alleles (13, 14). To-
gether, these results are consistent with the notion that
many of the peptides transported by TAP and many of the
epitopes presented by MHC class I are directly derived by
proteasomal proteolysis.
The presently available data on the substrate/ligand spec-
ificities of proteasomes, TAP, and MHC class I, in addition
to suggesting coordinated function of the three systems, ar-
gue for some degree of coevolution. It has been suggested
that peptide binding to MHC class I and class II may have
been determined by proteolytic pathways available in an-
cestors before emergence of the vertebrate immune system
(15). Here, we examine the hypothesis that proteasome-
mediated proteolysis may have influenced the evolution of
MHC class I. This hypothesis requires that the capacity of
proteasomes to generate fragments with the general struc-
tural features of MHC class I binding peptides is conserved
and extends back in evolution to before the emergence of
MHC and T cell recognition. Although structural homolo-
gies would anticipate a high degree of conservation in pro-
teasomal functions, differences in cleavage site usage be-
tween proteasomes at different stages of evolution have been
reported (16, 17)
 
.
 
 Furthermore, it has been suggested that
the IFN-
 
g
 
 inducible elements drastically alter the repertoire
of peptide products of proteasome mediated proteolysis (18,
19). Our results suggest that the capacity of proteasomes to
generate potentially immunocompetent peptides, including
the efficient generation of several proven MHC class I ligands,
is highly conserved in eukaryotes and evolved before the
vertebrate immune system. The functional modifications by
the IFN-
 
g
 
–inducible elements suggest an evolutionary ad-
aptation of proteasomes to their novel immune functions.
However, these modifications appear to be mainly quanti-
tative in nature and did not confer fundamentally novel
characteristics to proteasomal proteolysis.
 
Materials and Methods
 
Reagents, Cell Lines, and Antibodies.
 
The protease inhibitor
 
N
 
-acetyl-
 
l
 
-leucinyl-
 
l
 
-leucinal-
 
l
 
-norleucinal (LLnL) was pur-
chased from Sigma Chemical Co. (St. Louis, MO); IFN-
 
g
 
 was
from Boehringer Mannheim GmbH (Mannheim, Germany). The
proteasome inhibitor lactacystin was purified as described (20).
The C57BL/6-derived thymoma EL4, the human lymphoblas-
toid cell line T1, the human erythroblastoid cell line K562, and
 
Drosophila melanogaster
 
 Schneider cells were obtained from Amer-
ican Type Culture Collection (Rockville, MD). Monoclonal an-
tibodies were prepared from the hybridoma Y3 (anti-H2 class I
K
 
b
 
 heterodimers; 21). Rabbit antiserum specific for sequences en-
coded by exon 8 of the K
 
b
 
 gene and reactive with free or 
 
b
 
2
 
m-
associated K
 
b
 
 heavy chains was a gift from Dr. S. Nathenson (Al-
bert Einstein College, New York).
 
Immunoprecipitation Experiments.
 
EL4 cells (10
 
7
 
 cells/ml) were
incubated for 2 h at 37
 
8
 
C in the presence or absence of protea-
some inhibitors in cysteine and methionine-free medium, and for
the last 45 min of incubation, (
 
35
 
S) cysteine/methionine (700 
 
m
 
Ci/
ml) was added. After metabolic labeling, cells were lysed in 0.5%
Nonidet P-40 (ICN Biomedicals Inc., Plainview, New York) and
0.5% Mega 9 (Sigma Chemical Co.). Samples were precleared for
60 min at 4
 
8
 
C with protein A–Sepharose (Pharmacia, Uppsala,
Sweden) pretreated with 1 mg/ml bovine serum albumin. For
immunoprecipitation, either mAb Y3 (15 
 
m
 
g) or 4 
 
m
 
l rabbit 
 
a
 
exon 8 antiserum were added to the precleared lysates for 2 h. For
the last 90 min of incubation, protein A–Sepharose was added. 
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Immunoprecipitates were analyzed by SDS-PAGE on 12% gels.
Quantitation of gel bands was performed with the aid of a Fujix
BAS 1,000 phosphorimager.
 
Peptides and Protein Substrates.
 
Peptides were synthesized by
using solid-phase 9-fluorenylmethoxycarbonyl chemistry in a pep-
tide synthesizer (431A; Applied Biosystems, Foster City, CA) and
subsequently purified by reverse phase HPLC. The identity of pep-
tides was established by matrix-assisted laser desorption/ioniza-
tion time of flight mass spectrometry (MALDI-Tof-MS) and aa
sequence analysis on Hewlett-Packard Co. (Palo Alto, CA) in-
struments. Ribulose 1,5 bisphosphate carboxylase small subunit
was purified from intact pea chloroplasts by denaturing continu-
ous electrophoresis (Grimm, R., manuscript submitted).
 
Purification of 20S Proteasomes and of Recombinant PA28
 
a
 
.
 
20S proteasomes were purified from EL4 cells cultured with or
without 50 U/ml IFN-
 
g
 
 for 6 d, from K562, T1, and 
 
D. melano-
gaster
 
 Schneider cells, as well as from 
 
Saccharomyces cerevisiae
 
 (strain
YRG-2) by fractionated precipitation of the cytosol with poly-
ethylene glycol 6,000 followed by anion exchange chromatogra-
phy on a Mono Q column (HR 5/5; Pharmacia) as previously de-
scribed for EL4 cells (22). Modifications of the NaCl gradient
(buffer A: 20 mM Tris/HCl [pH 7.2]; buffer B: 20 mM Tris/HCl
[pH 7.2], 1 M NaCl) were as follows: 
 
S. cerevisiae
 
: 0–38% B in 50
min, 38–48% B in 25 min, proteasomes eluted at 45% B; 
 
D. mel-
anogaster
 
: 0–28% B in 50 min, 28–31% B in 25 min, proteasomes
eluted at 30% B; IFN-
 
g
 
–treated EL4 cells: 0–34% B in 65 min,
34–37% B in 40 min, proteasomes eluted at 36% B; K562 cells:
0–37% B in 55 min, 37–41% B in 40 min, proteasomes eluted at
38% B; T1 cells: 0–35% B in 55 min, 35–38% B in 40 min, pro-
teasomes eluted at 37% B. T1 proteasomes were further purified
on a Phenylsuperose column (Pharmacia). The proteasomes were
recovered in the flow-through fraction. 20S proteasomes from
 
Rhodococcus
 
 sp. and recombinant 
 
Thermoplasma acidophilum
 
 pro-
teasomes were purified as described (23, 24). The purity of pro-
teasomes was assessed by SDS-PAGE followed by silver staining
as described (22). Purification of recombinant human red blood
cell PA28
 
a
 
 is described in references 25 and 26.
 
Proteasome Digests and Analyses.
 
Digestions of synthetic pep-
tides (6 
 
m
 
g) and of the small subunit of ribulose 1,5 bisphosphate
carboxylase (10 
 
m
 
g) with isolated proteasomes (1 
 
m
 
g) were per-
formed at 37
 
8
 
C, except in the case of 
 
Thermoplasma
 
 proteasomes
at 60
 
8
 
C, in a total volume of 300 
 
m
 
l buffer (20 mM Hepes/KOH
[pH 7.0] 1 mM EGTA, 0.5 mM EDTA, 5 mM MgCl
 
2
 
, 0.5 mM
2-mercaptoethanol, 0.02% sodium azide). Digestions of ovalbumin
fragments Ova
 
37-77
 
 and Ova
 
239-281
 
, and of the protein substrate
were done in the presence of 0.004% SDS. In the experiments
shown in Fig. 7, recombinant PA28
 
a
 
 was added in a fivefold mo-
lar excess over the proteasome. Aliquots of the reaction mixture
were separated by reverse phase HPLC on a SMART system
equipped with a 
 
m
 
RPC C2/C18 SC 2.1/10 column (Pharmacia).
Eluent A was 0.1% (vol/vol) TFA/water; eluent B was 80% (vol/
vol) acetonitril/water (0.081% TFA). The identity of peptides in
individual HPLC fractions was established by MALDI-Tof-MS
and aa sequence analysis by Edman degradation.
For molecular mass determination without separation of the
peptide products, the reaction mixtures were desalted with the help
of a mini-C18 column. The peptides were then eluted by the addi-
tion of 60% acetonitril in water, concentrated, and then directly
analyzed with a 62025A Maldi-Tof-MS (Hewlett-Packard Co.)
using dihydroxybenzoic acid as the matrix.
For proteasome cleavage site determination, aliquots of the re-
action mixtures were directly subjected to aa sequence analysis by
Edman degradation (pool sequencing). The sites and efficiencies
of cleavage were determined from the sequence cycles and rela-
tive yields of amino acids unique in the analyzed sequence. For
example, if the unique amino acid 
 
X
 
 appears in cycle 
 
Y
 
 of Edman
degradation, a cleavage site is revealed 
 
Y
 
 residues from amino acid
 
X
 
 towards the NH
 
2
 
 terminus; if the unique amino acid appears in
more than one cycle, several cleavage sites are revealed, their rel-
ative strengths corresponding to the relative yields of the aa in
each cycle.
 
Results
 
Marked Inhibition of the Assembly of MHC Class I Molecules
by the Proteasome Inhibitor Lactacystin.
 
A functional pres-
sure of proteasome-mediated proteolysis on the evolution
of MHC class I could be envisaged if proteasomal digestion
provided the major source of peptides for assembly with
MHC class I. We examined the assembly of MHC class
I–peptide complexes in the presence of the proteasome in-
hibitor lactacystin (27). Except proteasome-related particles
in bacteria (28), no other protease has been reported to be
inhibited by this compound. The murine thymoma cell line
EL4, expressing the class I molecules H-2K
 
b
 
 (K
 
b
 
) and H-2D
 
b
 
(D
 
b
 
), was incubated with or without lactacystin and meta-
bolically labeled with 35S-methionine plus cysteine. Immu-
noprecipitation was performed either with mAb Y3, de-
tecting a conformational determinant of Kb present only on
the assembled trimolecular complex, or with an antiserum
(anti–exon 8 antiserum) that recognizes the cytoplasmic tail
of Kb and Db molecules, independent of whether a peptide
is bound or not. As shown in Fig. 1, addition of lactacystin
caused a marked decrease in the amount of Kb molecules
precipitable with the conformation-specific antibody, but
not of that precipitated by the anti–exon 8 reagent. Plateau
inhibition was at z67% as calculated by phosphorimaging
(see Materials and Methods), similar or slightly better than
Figure 1. Lactacystin inhibits the assembly of Kb class I molecules. Au-
toradiograms of immunoprecipitated Kb heavy chains from 35S-labeled
EL4 cells. EL4 cells (107) were mock-treated for 2 h with DMSO, or with
LLnL (100 mM), or with various concentrations of lactacystin. Concen-
trations of lactacystin between 100 and 1,000 mM gave maximal inhibition.
Only one concentration (250 mM) is shown. [35S]methionine/cysteine
(0.7 mCi/ml) was added for the last 45 min of incubation. Detergent ly-
sates were precleared and immunoprecipitated with either the conforma-
tion-dependent anti-Kb mAb Y3 or a conformation-independent anti-Kb
exon 8 immunoglobulin preparation. Immunoprecipitates were separated
by a 12% SDS-PAGE gel and autoradiographed.212 Role of Proteasomes in the Evolution of MHC Class I
that reported for the peptide aldehyde inhibitor LLnL (Fig. 1;
reference 10). These data are in agreement with recent re-
sults on the inhibition of antigen presentation by lactacystin
(29) and further support the notion that proteasomes par-
ticipate in the generation of the majority of peptides pre-
sented by MHC class I.
Efficient Generation of Proven MHC Class I Ligands by Pro-
teasomes of Eukaryotic Invertebrates. At early time points in
the processing of short polypeptide substrates by isolated
mouse 20S proteasomes, single cleavage intermediates can
be detected in addition to dual cleavage oligopeptides. Af-
ter consumption of the original substrate and of the single
cleavage intermediates, the reaction appears to slow down
and the mixture of peptide fragments approaches a rela-
tively stable state (12). We believe that the stable state in
vitro most closely resembles the conditions in vivo. There-
fore, although several time points have been analyzed to
compare 20S proteasomes at distinct stages of evolution
(Fig. 2), we present data on the relatively stable product
patterns determined after complete substrate turnover.
We have previously shown that the immunodominant
ovalbumin epitope Ova257-264 (SIINFEKL; reference 30) is
the major stable product generated by mouse 20S protea-
somes from the 22-mer OvaY249-269 as well as from the 44-
Figure 2. Polyacrylamide gel electrophoresis of purified proteasomes.
Proteasomes were isolated from various organisms or cell lines as de-
scribed in Materials and Methods and analyzed by SDS-PAGE on 12%
gels followed by silver staining. The low molecular mass polypeptides be-
tween 22 and 35 kD represent the subunits of 20S proteasomes. Lane 1,
Thermoplasma acidophilum; lane 2, Rhodococcus sp.; lane 3, S. cerevisiae; lane
4, D. melanogaster; lane 5, mouse EL4 cells; lane 6, human T1 cells.
Figure 3. Proteasomes from eukaryotic invertebrates have the capacity
to efficiently generate known MHC class I ligands. (A) Digestion of the
44-mer Ova239-281 with 20S proteasomes isolated from D. melanogaster
Schneider cells. The proteasome cleavage sites indicated by the arrows above
the sequence were determined by Edman degradation pool sequencing
(for raw data see Fig. 5 B). Reverse phase HPLC chromatogram of the
peptide mixture is shown below. The mass spectrometry inset refers to
the peak that contains the immunodominant CTL epitope SIINFEKL. (B
and C) Digestion of the 24-mer BTG197-120 with 20S proteasomes iso-
lated from S. cerevisiae. (B) Proteasome cleavage site determination by Ed-
man degradation pool sequencing. For interpretation of pool-sequencing
data, see legend to Fig. 5. (C) Reverse phase HPLC chromatogram. The
numbered peaks contain the peptides LLPSEL (1), TLWVDPYE (2), and
the HLA A2.1 ligand TLWVDPYEV (3). (D) Digestion of the 21-mer
JAK1348-368 with 20S proteasomes isolated from D. melanogaster Schneider
cells. Proteasome cleavage sites indicated by the arrows above the se-
quence were determined from the peptide products identified in the re-
verse phase HPLC chromatogram shown below. The numbered peaks
contain the peptides REEWNNF (1), REEWNNFSY (2), SYFPEI (3),
and the Kd ligand SYFPEITHI (4). All peptide mixtures shown were ana-
lyzed after substrate consumption. The peptides contained in the peaks
marked with numbers and/or mass spectrometry inserts were identified
by Maldi-Tof-MS (insets) and Edman degradation (not shown).213 Niedermann et al.
cleavage sites reside after the same hydrophobic (L264-T265)
and acidic (E256-S257) aa. These cleavage sites precisely co-
incide with the NH2- and COOH-terminal epitope bound-
aries. In contrast, the cleavage pattern of archaebacterial
proteasomes is clearly different; they prefer to cleave after
mer Ova239-281 (12). Here we show that this octamer is also
a dominant product of digestion of Ova239-281 by 20S pro-
teasomes isolated from D. melanogaster Schneider cells (Fig.
3 A and Fig. 4 A). As a second example, we studied the
generation of the nonamer TLWVDPYEV, an endogenous
peptide derived from the product of the antiproliferative B
cell translocation gene 1 (BTG1) and eluted as a major self-
epitope from the human class I molecule HLA-A2.1 (31).
Fig. 3, B and C show that this nonamer peptide is the ma-
jor dual cleavage product generated by yeast (S. cerevisiae)
proteasomes of the synthetic 24 mer encompassing this
peptide in the sequence of BTG1. Moreover, we studied a
21-mer sequence derived from the tyrosine kinase JAK1
containing the nonamer SYFPEITHI, the most abundant
self-peptide presented by mouse H-2Kd molecules of P815
cells (32, 33), and previously shown to be generated by di-
gestion with mouse 20S proteasomes (34). We detected the
epitope as the predominant dual cleavage product of the 21
mer with Drosophila proteasomes (Fig. 3 D). Thus, protea-
somes from invertebrate eukaryotes have a high potency to
generate proteolytic fragments that have been proven to
serve as ligands of MHC molecules in the vertebrate im-
mune system.
The Majority of Dual Cleavage Peptides Produced by Inverte-
brate Proteasomes Are in Size Range of MHC Class I Ligands.
More than 90% of the peptides so far eluted from MHC
class I molecules are 8–10 aa in length (3). We have re-
cently shown that more than half of the dual cleavage pro-
teolytic fragments generated by digestion of Ova239-281 with
mouse 20S proteasomes are 8–11 aa in length (12). In Fig.
4, A and B, we show that the peptides most efficiently pro-
duced from this substrate by Drosophila 20S proteasomes are
in the size range of MHC class I–binding peptides (Fig. 4
B, shaded area). In addition, we studied a longer and immu-
nologically undefined substrate, the 123-aa small subunit
(SSU) of ribulose 1,5 bisphosphate carboxylase from the
garden pea (Pisum sativum L.) (Fig. 4, C–E). Digests were
prepared with proteasomes from mouse EL4 cells and from
yeast. Most of the abundant masses in the digests repre-
sented peptide sizes of 5 to 11 aa for EL4 proteasomes or 5
to 13 aa for yeast proteasomes. In both cases, the majority
of the peptides were 8–10 mer (Fig. 4, D and E, shaded ar-
eas). The masses of a number of abundant products are
identical or nearly identical in the digests in Fig. 4, D and
E, indicating that many of the peptides produced from SSU
by mouse and yeast proteasomes may be identical.
Conserved General Cleavage Site Specificity of Proteasomes
from Vertebrates and from Eukaryotic Invertebrates. We stud-
ied the cleavage site (...P3P2P1 2 P19P29P39...) preferences in
polypeptides of 20S proteasomes isolated from a variety of
organisms including archaebacteria, eubacteria, and nonver-
tebrate and vertebrate eukaryotes (see Fig. 2). Fig. 5 A shows
the results obtained by pool sequencing of digests of the
22-mer OvaY249-269 containing the immunodominant
Ova257-264 (SIINFEKL) epitope. The cleavage patterns of all
proteasomes of eukaryotic origin, including the murine cell
line EL4, the human cell lines T1 and K562, as well as of in-
sects and of yeast are remarkably similar; the predominant
Figure 4. Most peptides efficiently produced by 20S proteasomes from
invertebrate eukaryotes fall into the size range of MHC class I ligands.
The 44-mer peptide Ova239-281 (A and B) and the 123-aa SSU of ribulose
1,5 bisphosphate carboxylase (C, D, and E) were digested with isolated
proteasomes. After substrate consumption, the resulting peptide mixtures
were subjected to MALDI-Tof-MS. (B) Mass spectrum of the peptide
mixture obtained upon digestion of Ova239-281 with D. melanogaster pro-
teasomes. The mass peak representing the immunodominant OVA
epitope SIINFEKL (theoretical mass: 964.3) is indicated. (D and E) Mass
spectra of the peptides mixtures obtained upon digestion of SSU with
proteasomes isolated from the murine cell line EL4 (D) and from yeast
(E). The shaded areas in B, D and E mark the mass range of 8–10-mer
peptides, i.e., the typical size range of MHC class I ligands. The mass
ranges of all overlapping peptides of Ova239-281 and SSU are indicated in A
and C, respectively. In the SSU digests with proteasomes isolated from
EL4 cells (D) or from yeast (E), 56.7 and 58.6%, respectively, of all dis-
cernible masses fell into the size range of 8–10-mer peptides.214 Role of Proteasomes in the Evolution of MHC Class I
aromatic (F261-E262) and aliphatic aa (L264-T265, L255-E256),
no cleavage after acidic aa is seen, and the major cleavage
site destroys the epitope. Analyses of the degradation of
longer substrates is shown in Fig. 5, B and C. The 44-mer
Ova239-281 (Fig. 5 B) represents a longer fragment contain-
ing the immunodominant SIINFEKL; the 41-mer Ova37-77
(Fig. 5 C) contains the poorly immunogenic epitope Ova55-62
(KVVRFDKL), also presented by Kb (22, 35). For bacterial
proteasomes, the data in Fig. 5 C highlight the preference
for aromatic and aliphatic aa in P1, whereas cleavage after
charged aa is rare but not impossible (Fig. 5 B). Cleavage
patterns of all eukaryotic examples, although not fully iden-
tical, reflect the same broad but characteristic P1 specificity
spectrum. About 60–65% of the peptide bonds hydrolyzed
(e.g., 11/17 in Ova239-281 by mouse EL4-proteasomes; 11/18
by yeast proteasomes) have an aromatic or a hydrophobic
aliphatic aa in the P1 position. Most of the remaining pep-
tide bonds have either a positively (R) or negatively
charged (E, D) aa in the P1 position. In addition, together
with results in Fig. 3 (see above), these data extend to inver-
tebrate eukaryotes our previous finding that proteasomes
have a preference for small or polar aa in the P19 position of
the scissile bond (12). Major cleavage sites are: E256-S257
and L264-T265 in OvaY249-269 (Fig. 5 A), L102-T103 and V111-
S112 in BTG197-120 (see Fig. 3, B and C), and F354-S355 in
JAK1348-368 (see Fig. 3 D).
Functional Effects of IFN-g–Inducible Elements of Vertebrate
Proteasomes. The existence of IFN-g–inducible proteasomal
elements in vertebrates indicates that the proteasomes them-
selves have evolved by adapting to their novel immunolog-
ical role. If the specificity of proteasomal proteolysis was
drastically and qualitatively altered by the IFN-g–inducible el-
ements, a significant restricting role of proteasomes in the
evolution of MHC would be less likely. Most previous
studies on the functional effects of the IFN-g–inducible b
subunits LMP2, LMP7, and MECL1 used short (3–4 aa)
fluorogenic substrates, and inconsistent changes in pepti-
dase activities have been reported by different investigators.
By digesting polypeptide sequences more likely to resemble
physiological proteasome substrates, we compared protea-
somes from untreated with that of IFN-g–treated EL4
Figure 5. Proteasomes from vertebrates and from eukaryotic inverte-
brates show highly conserved cleavage patterns in polypeptides. Synthetic
peptides OvaY249-269 (A), Ova239-281 (B), and Ova37-77 (C) were incubated
in the presence of 20S proteasomes isolated from the indicated cell lines
or organisms. After substrate consumption, the mixtures were subjected
to pool sequencing by Edman degradation. Proteasome cleavage sites
were determined and quantitatively estimated by the sequence cycle num-
bers and the yields of unique amino acids. For example, the strong signal
for asparagine (N) in sequence cycle 4 (panel A) indicates a strong cleav-
age site four residues towards the NH2 terminus of N between E-S. Al-
though isoleucine (I) is not unique, these signals are necessary for the in-
terpretation of the phenylalanine (F) signal, and are therefore included in
panel B. I undergoes racemization to iso- and alloleucine, the latter repre-
senting 30-40% and coeluting with F. The phenylalanine signals in cycles
2 and 3 are therefore caused by isoleucine (e.g., EL4 digest). Cleavage
sites are indicated by arrows, with the sizes reflecting estimates of the rel-
ative efficiency of cleavage. The CTL epitopes SIINFEKL and KVVR-
FDKL are underlined.215 Niedermann et al.
cells. Enhanced expression of LMP2 and LMP7 in induced
compared to uninduced cells was monitored by Western
blot analyses (not shown). Fig. 6, A and B show the HPLC
patterns obtained upon digestion of OvaY249-269, Fig. 6, C
and D that of the BTG1-derived 24 mer. In both cases, we
observe that proteasomes from IFN-g–treated cells generate
increased amounts of fragments with hydrophobic COOH
termini (YVSGLEQL is peak 4 in Fig. 6, A and B, and TL-
WVDPYEV is peak 4 in Fig. 6, C and D) and decreased
amounts of fragments with acidic COOH termini (YVS-
GLE is peak 2, and YVSGLEQLE is peak 3 in Fig. 6, A
and B; TLWVDPYE is peak 2 in Fig. 6, C and D). This is
in line with general preferences of MHC class I molecules,
although it does not necessarily result in improved produc-
tion of each individual epitope; production of BTG1103-111
(TLWVYPDEV, peak 4 in Fig. 6, C and D) is improved,
whereas production of Ova257-264 (SIINFEKL, contained in
peak 5, theoretical mass: 963.14, in Fig. 6, A and B) is im-
paired. In spite of these quantitative changes, however, the
same set of major proteolytic fragments is produced by pro-
teasomes isolated from uninduced and from IFN-g–induced
cells.
The IFN-g–inducible PA28 enhancer, existing in two
homologous forms, a and b (25, 36), binds as a ring-like
hexa/heptameric structure to the a endplates of the 20S pro-
teasome (37). PA28-capped 20S proteasomes exhibit en-
hanced activity towards short fluorogenic model substrates
(26, 38–40). Here we analyze the effects of recombinant
PA28a on the digestion of the 22-mer OvaY249-269 by 20S
proteasomes (Fig. 7). Addition of PA28a leads to a slightly
increased turnover of the substrate and reverses the ratio
between HPLC peak 4 (SIINFEKL and ESIINFEKL) and
HPLC peak 5 (SIINFEKLTEWTS and ESIINFEKLTE-
WTS). The peptides in peak 4 represent dual cleavage frag-
ments; those in peak 5 are produced by a single cleavage
only. Thus, in the presence of PA28a, the rate of accumu-
lation of dual cleavage peptides is relatively increased, in
line with results recently reported for native PA28 presum-
ably consisting of both a and b isoforms (34). However,
the dual cleavage peptides that are more efficiently pro-
duced in the presence of the activator are generated also
in its absence. Together, these results support the notion
that the IFN-g–inducible proteasomal elements, including
PA28 as well as the inducible b-type subunits, modify the
20S-proteasome in such a way that the generation of im-
munocompetent peptides is quantitatively improved, with-
out drastic alterations of the specificity of proteasomal pro-
teolysis.
Discussion
The work presented in this paper was stimulated by our
observation that each of three proven MHC class I ligands
was found as a major proteolytic fragment upon digestion
of precursor polypeptides with yeast and/or insect protea-
somes. One possible way to rationalize this observation was
that the preexisting proteolytic fragments of proteasomes
provided an important evolutionary force in shaping the
peptide binding groove of MHC class I molecules. Such a
mechanism would predict that proteasomal digestion would
be the major source of MHC class I ligands in immunolog-
ically competent vertebrates. The evidence in favor of this
notion is in part circumstantial and is a matter of continu-
Figure 6. Proteasomes from IFN-g–treated cells generate more pep-
tides with hydrophobic and fewer peptides with acidic COOH termini
from polypeptides. The substrates OvaY249-269 (A and B) and BTG197-120
(C and D) were incubated in the presence of 20S proteasomes from un-
treated EL4 cells (A and C) or EL4 cells treated with IFN-g (B and D).
The sequences of the substrates are given in Fig. 5, A and B, respectively.
After consumption of the substrates, the peptide mixtures were separated
by reverse phase HPLC. Peptides contained in the peaks marked with
numbers are: (A and B) TEWTS (1), YVSGLE (2), YVSGLEQLE (3),
YVSGLEQL (4), ESIINFEKL and the Kb ligand SIINFEKL (5), and SI-
INFEKLTEWTS/ESIINFEKLTEWTS (6); (C and D) LLPSEL (1),
TLWVDPYE (2), TLWVDPYEVS (3), the HLA-A2.1 ligand TLWVD-
PYEV (4), and TLWVDPYEVSY (5). Peptides were identified by MALDI-
Tof-MS and Edman degradation.216 Role of Proteasomes in the Evolution of MHC Class I
ing debate. We show that lactacystin, specific proteasome
inhibitor until otherwise demonstrated, inhibits the assem-
bly of about two-thirds of newly synthesized MHC class I
heavy chains with b2m. Inhibition of recognition of a panel
of cytotoxic T lymphocyte epitopes by lactacystin has re-
cently been reported (29). Although protease inhibitors
cannot provide definitive proof, the combined data on this
and other (10) proteasome inhibitors suggest that protea-
somes are critically involved in the generation of peptides
for assembly with MHC class I. In addition, data from this
and other laboratories (12, 34, 41) suggest that proteasomes
often are involved in the final proteolytic steps of epitope
generation.
A given MHC class I molecule can accommodate large
arrays of different peptides. Typically, peptide specificity is
constrained by two binding pockets, whereas the rest of the
peptide sequence may vary. This is reminiscent of many en-
doproteases whose active sites can accommodate many dif-
ferent peptide sequences. In many of these enzymes, the pri-
mary determinant of substrate specificity is the S1 subsite,
accommodating the P1 residue of the scissile bond P1–P19.
The F pocket of MHC class I molecules accommodates the
side chain of the aa at the COOH terminus of the peptide
with a strong preference for aliphatic, aromatic, and charged
aa. Except for negatively charged residues, the P1 prefer-
ence of proteasomes closely resembles the preferences of
the F pocket. The F pocket may therefore represent the
structural center of the relationship of MHC class I mole-
cules to the proteasome. Nevertheless, no class I allele has
been found so far whose F pocket prefers peptides with
acidic COOH termini, although these are also efficiently
produced by proteasomes of vertebrates and invertebrates.
This may be taken as an indication that MHC class I mole-
cules evolved independently of proteasomes and that their
preference for aliphatic, aromatic, or positively charged
COOH termini has other reasons. However, it is also pos-
sible that there was selection against acidic amino acid side
chains in the COOH-terminal ligand position. For exam-
ple, it is conceivable that an acidic COOH-terminal aa side
chain interferes with the formation of the H-bond system
between conserved polar residues of class I and the free
backbone carboxylate of the ligand. During the approach
of a peptide with an acidic COOH-terminal aa side chain,
the side-chain carboxylate, instead of the backbone carbox-
ylate, may become engaged in H-bond formation, prevent-
ing proper anchoring of the ligand in the pockets of the
peptide binding groove. Furthermore, peptides with acidic
COOH termini may not be correctly handled by other com-
ponents of the processing and presentation machinery, such
as heat shock proteins (hsp), which have been proposed to
shuttle peptides in the class I pathway (42), or TAP. How-
ever, at least human TAP has been shown to translocate
peptides with acidic COOH termini (43).
Our pool-sequencing data strongly support the high de-
gree of conservation among eukaryotes of the cleavage site
usage in polypeptides by 20S proteasomes. Although cleav-
age efficiencies of individual peptide bonds are not always
identical, the P1 specificities of both vertebrate and inverte-
brate eukaryotic proteasomes are confined by the same
broad, but well-defined, limits. The same applies to the P19
position where we frequently see small or polar side chains,
particularly in major cleavage sites. For example, in the
BTG1-derived sequence, yeast 20S proteasomes most effi-
ciently hydrolyzed bonds that contain a small and/or polar
P19 residue (L-T, V-S), in addition to a suitable P1 residue.
Similar preferences were seen in OvaY249-269 (E-S, L-T) and
Figure 7. PA28a enhances the rate of accumulation of dual cleavage
products without changing the cleavage site specificity of the proteasome.
The substrate OvaY249-269 (for the sequence, see Fig. 5 A) was incubated
with 20S proteasomes from EL4 cells in the absence (A and C) or pres-
ence (B and D) of recombinant PA28a. At the time points indicated, the
mixtures were separated by reverse phase HPLC. The peptides in the
peaks marked with numbers are: TEWTS (1), YVSGLEQLE (2), YVS-
GLEQL (3), ESIINFEKL and the Kb ligand SIINFEKL (4), SIINFEK-
LTEWTS and ESIINFEKLTEWTS (5), YVSGLE (6), SIINFE (7), and
SIINF (8). The large peak at the right of A and B is undigested substrate.
Peptides were identified by MALDI-Tof-MS and Edman degradation.217 Niedermann et al.
JAK1348-368 (F-S). Statistical analysis of so far eluted MHC
class I ligands revealed an enrichment of small and polar
residues in the NH2-terminal position (most significantly S,
but also G and A) (12). In addition, a recent analysis of
Db-binding ligands has shown a significant enrichment for
S, T, and C in the NH2-terminal position of high affinity
peptides (44). Moreover, small polar peptide NH2 termini
favor hydrogen bond formation in HLA-B27 (5). Also,
TAP is known to have enhanced binding/translocation effi-
ciency for peptides with small or polar residues (45; P. van
Endert, personal communication). We favor the hypothesis
that these structural features of the peptide-binding groove
of MHC class I, and perhaps also of the peptide-binding
site of TAP, may represent evolutionary adaptations to
conserved features of proteasomal proteolysis.
A striking property of proteasomes is the defined length
of their proteolytic fragments. For archaebacterial protea-
somes, peptide length centers around 7 and 8 mers (46).
Upon digestion of 22- and 44-mer OVA-derived polypep-
tides by mouse 20S proteasomes, we have recently ob-
served that the majority of the dual cleavage peptide prod-
ucts were 8–11 mer. Peptides of this length dominated
among the dual cleavage products at all time points tested,
including early in the time course. Many of the peptides of
this length are relatively stable, even upon prolonged diges-
tion by proteasomes (12). Most MHC class I molecules
bind 8–10/11-mer peptides (3). Nonamers seem to be pre-
ferred by most alleles. In this report, we show that a major
proportion of the stable peptides generated by yeast and D.
melanogaster proteasomes fall into the size range preferred by
MHC class I. Thus, the putative evolutionary relationships
between proteasomes and MHC class I may include the
length of the peptide-binding groove. In addition, the highly
conserved clusters of polar aa at both ends of the peptide bind-
ing groove may have evolved to facilitate efficient H-bond
formation with the ends of the short peptides produced by
proteasomes.
IFN-g is a pivotal cytokine in the function of the im-
mune system and the incorporation of IFN-g–inducible el-
ements into the structure of proteasomes is highly sugges-
tive of an evolutionary adaptation to the requirements of
the immune system. One of the IFN-g–inducible b sub-
units, LMP7, is first detected in the nurseshark (47), i.e., at
the same phylogenetic step as most other elements of the
vertebrate immune system (48). It was therefore possible
that MHC molecules evolved independently of protea-
somes followed by a unidirectional adaptation of protea-
somes to the requirements of MHC class I. On the other
hand, as shown in the present paper, the ability of protea-
somes to generate potentially immunocompetent peptides
preceded the evolution of the MHC, suggesting the reverse
order of adaptation. We were therefore interested in un-
derstanding the extent of functional modification inflicted
upon proteasomes by IFN-g–inducible elements.
Based on experiments with fluorogenic tri- and tetra-
peptides, IFN-g–dependent alterations in the substrate spe-
cificity of proteasomes were reported. In the first reports on
this subject, the authors observed that proteasomes isolated
from IFN-g–treated cells gained about twofold higher chy-
motrypsin-like (Suc-LLVY-MCA–hydrolyzing) and trypsin-
like (Boc-LLR-MCA–hydrolyzing) activities (49, 50), but
lost about half of the postglutamyl (Clz-LLE-MNA–hydro-
lyzing) activity (49). The authors suggested that these func-
tional alterations should favor the degradation of proteins to
peptides that terminate in hydrophobic and basic residues
that are usually found bound to MHC class I. These results
were confirmed by some (51), but not by others (18, 52,
53). Studies using polypeptide substrates have yielded re-
sults inconsistent with each other and with that obtained
with fluorogenic substrates (18, 41). Taken together, the func-
tional consequences of the incorporation of IFN-g–inducible
b subunits remain incompletely understood.
Using as substrates 22- and 24-mer polypeptide se-
quences corresponding to natural proteins, we show that
the characteristic P1 specificity spectrum of proteasomes re-
mains qualitatively unchanged in proteasomes isolated from
IFN-g–treated cells. However, as shown for the first time
with polypeptide substrates, we see enhanced hydrolysis of
individual peptide bonds with hydrophobic P1 residues by
proteasomes of IFN-g–treated cells compared to that of
untreated cells. In addition, we see reduced cleavage of
neighboring peptide bonds with acidic P1 residues. Thus,
the data presented here for polypeptide substrates agree
with that first reported by Gaczynska et al. with short fluo-
rogenic substrates (49). However, together with our results,
the rather mild defects of mice genetically deficient in
LMP2 or LMP7 (54, 55), as well as the restoration of anti-
gen presentation in LMP2/LMP7/TAP triple-deficient T2
cells by transfection with TAP alone (56–59), argue against
drastic qualitative alterations in the cleavage preferences of
proteasomes by IFN-g–inducible b subunits.
Another IFN-g–inducible element is the enhancer PA28.
Recently, Dick et al. reported for the degradation of 19–25-
mer substrates by 20S proteasomes, a substantially enhanced
rate of accumulation of dual cleavage products by addition
of PA28 (34). Here we show that recombinant PA28a is
sufficient to induce this effect. This is in line with the
recent finding that transfection of PA28a is sufficient to
improve the recognition of virus-infected cells by CTLs
(60). However, with and without PA28, the same cleavage
sites are used and the same products are generated. Thus,
the highly conserved general cleavage specificity of the 20S
proteasome remains unchanged in the presence of PA28.
Nevertheless, PA28 might have been evolved to optimize
the capacity of the 20S proteasome for oligopeptide gener-
ation, in particular from short substrates.
Evolutionary relationships have been invoked between
MHC class I and the hsp70 family of chaperones (61, 62).
However, recent structural studies (63, 64) indicate that the
homologies between the peptide-binding regions of hsp70
and MHC molecules are less than originally anticipated. Ob-
servations suggesting evolutionary links between protea-
somes, MHC, TAP, and perhaps hsp70 were recently re-
ported by Kasahara et al. (65) and Katsanis et al. (66). Both
the human and the mouse genomes contain three regions
with striking homology to the MHC complex, as they com-218 Role of Proteasomes in the Evolution of MHC Class I
prise genes coding for proteasome b-type subunits, ABC
transporters, hsp70, NOTCH, and complement compo-
nents. One of these regions, in addition, harbors the gene
for CD1. They speculate that the MHC complex and these
homologous regions might have been generated by dupli-
cation of an ancestral syntenic group in jawless fish, i.e., be-
fore emergence of T cell recognition. This implies that
MHC class I–like molecules, and perhaps also TAP, may
have existed before the adaptive immune system.
Due to their role in the degradation of unfolded poly-
peptides, proteasomes are adapted to cleave hydrophobic
sequences from the inside of proteins. Most of the abun-
dant self-peptides eluted from MHC class I are derived from
highly conserved hydrophobic regions of a restricted set of
evolutionary conserved ubiquitous intracellular proteins (67).
In view of the possible existence of MHC class I before T cell
recognition, it is conceivable that the functional coopera-
tion between proteasomes and the precursor of MHC class
I was originally designed to present self-peptides and to
serve a purpose other than self–nonself discrimination, for
example, inhibition of NK killing. MHC polymorphism
and T cell recognition may have evolved subsequently,
thus accommodating the greater variety of foreign peptides.
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Note added in proof. While this article was in print, the x-ray structure of the yeast 20S proteasome was re-
ported (Groll, M., L. Ditzel, J. Löwe, D. Stock, M. Botchler, H.D. Bartunik, and R. Huber. 1997. Structure
of the 20S proteasome from yeast at 2.4 A resolution. Nature (Lond.). 386:463–471). The results are in excel-
lent agreement with the length distribution of proteasomal fragments and with the alterations by IFN-g–induc-
ible elements described in this paper.
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